Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME and Bioavailability of Pirtobrutinib in Healthy Males
NCT06180954Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pirtobrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity, Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration and 12 more. Started Sep 2020; status: completed.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06180954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06180954.